proxyvotesnow.com

Home › Companies › VIR BIOTECHNOLOGY INC. › 2023-2024

VIR BIOTECHNOLOGY INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and VIR BIOTECHNOLOGY INC.’s Form 8-K, filed 2024-05-29 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 6Ballot items
  • 229Asset managers
  • 1,653Fund votes
  • 2024-05-29Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore VIR BIOTECHNOLOGY INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by VIR BIOTECHNOLOGY INC.

These tallies are VIR BIOTECHNOLOGY INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-29 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VIR BIOTECHNOLOGY INC. — official shareholder meeting results, meeting held 2024-05-29
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Marianne De Backer, M.Sc., Ph.D., MBA 105,598,679---- 1,121,74812,252,827 Majority: yes
Elect Director: Norbert Bischofberger, Ph.D. 80,025,502---- 26,694,92512,252,827 Majority: yes
Elect Director: Ramy Farid, Ph.D. 106,416,937---- 303,49012,252,827 Majority: yes
Elect Director: Robert Nelsen 67,895,334---- 38,825,09312,252,827 Majority: yes
Proposal 2. Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers. 83,922,78922,639,307158,331 --12,252,827 Majority: yes
Proposal 3. Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's in 118,125,237679,046168,971 --0 Majority: yes

Source: VIR BIOTECHNOLOGY INC., Form 8-K, filed with the SEC on 2024-05-29 — read the filing on EDGAR.

How asset managers voted at the VIR BIOTECHNOLOGY INC. 2023-2024 meeting

Each item below shows how the 229 asset managers that disclosed a VIR BIOTECHNOLOGY INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 11 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST 21%
FOR: 83,922,789AGAINST: 22,639,307

VIR BIOTECHNOLOGY INC.’s own tally for this item (“Proposal 2. Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”): 83,922,789 for, 22,639,307 against, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 135,843,560 outstanding shares: 62% for, 17% against (78% of the company cast a for/against vote).

The 228 asset managers below cast 67% of the shares they voted on this item FOR (66,656,075 for, 32,801,498 against).

FOR 67%AGAINST 33%
FOR: 66,656,075 (66.9%)AGAINST: 32,801,498 (32.9%)ABSTAIN: 112,490 (0.1%)NOT VOTED: 41 (0.0%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at VIR BIOTECHNOLOGY INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
SB INVESTMENT ADVISERS (UK) LTD16,684,0410 00For
BlackRock15,163,624115,175 00For
ARCH Venture Management, LLC12,916,6630 00For
Vanguard12,373,22169,400 00For
State Street104,99511,942,246 00Against
BAILLIE GIFFORD & CO LTD3,821,0330 00For
Citadel2,186,2520 00For
GEODE CAPITAL MANAGEMENT, LLC01,921,289 00Against
Fidelity76,3131,830,943 00Against
Charles Schwab01,598,410 00Against
Bill & Melinda Gates Foundation1,559,1420 00For
Northern Trust873,3244,320 00For
Renaissance0877,147 00Against
BRIDGEWAY CAPITAL MANAGEMENT, LLC0810,700 00Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC0774,035 00Against
BRIDGEWAY FUNDS INC0769,000 00Against
Invesco0693,819 00Against
MELLON INVESTMENTS Corp0684,676 00Against
JPMorgan0682,567 00Against
ORBIMED ADVISORS LLC0640,000 00Against
DE Shaw0606,911 00Against
Dimensional0555,239 00Against
Capital Group90516,800 00Against
PRINCIPAL GLOBAL INVESTORS0462,030 00Against
EA Series Trust0458,044 00Against

Showing the 25 largest of 228 asset managers. See all 228 in the interactive database.

2. To elect the following four nominees for director to hold office until the 2027 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Marianne De Backer, M.Sc., Ph.D., MBA

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 105,598,679WITHHELD: 1,121,748

VIR BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Marianne De Backer, M.Sc., Ph.D., MBA”): 105,598,679 for, 1,121,748 withheld, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 135,843,560 outstanding shares: 78% for, 0.9% withheld (79% of the company cast a for/withheld vote).

The 73 asset managers below cast 100% of the shares they voted on this item FOR (36,873,274 for, 0 against).

FOR 99%
FOR: 36,873,274 (98.7%)ABSTAIN: 471,471 (1.3%)
Largest asset managers voting on “To elect the following four nominees for director to hold office until the 2027 Annual Meeting of Stockholders” at VIR BIOTECHNOLOGY INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,290,7110 00For
BlackRock11,421,0080 00For
State Street5,172,2090 6,6270For
Fidelity1,901,3400 00For
Charles Schwab769,4300 00For
BRIDGEWAY FUNDS INC769,0000 00For
EA Series Trust458,0440 00For
Dimensional00 435,7040Abstain
Invesco325,2040 00For
JPMorgan317,4650 00For
Columbia Threadneedle272,4560 00For
Capital Group258,4000 00For
Equitable228,7700 00For
Jackson National195,8000 13,9840For
TIAA205,3580 00For
Global X197,6300 00For
Direxion Shares ETF Trust183,7730 00For
QUANTITATIVE MASTER SERIES LLC148,2300 00For
American Century147,1120 00For
BNY Mellon126,5250 00For
Royce102,9000 00For
Principal98,1060 00For
ProShares97,5180 00For
ALPS ETF Trust95,2420 00For
Lincoln Financial70,3000 5,5660For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

3. To elect the following four nominees for director to hold office until the 2027 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Norbert Bischofberger, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%WITHHELD 25%
FOR: 80,025,502WITHHELD: 26,694,925

VIR BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Norbert Bischofberger, Ph.D.”): 80,025,502 for, 26,694,925 withheld, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 135,843,560 outstanding shares: 59% for, 20% withheld (79% of the company cast a for/withheld vote).

The 73 asset managers below cast 100% of the shares they voted on this item FOR (18,837,731 for, 0 against).

FOR 50.4%ABSTAIN 49.6%
FOR: 18,837,731 (50.4%)ABSTAIN: 18,507,014 (49.6%)
Largest asset managers voting on “To elect the following four nominees for director to hold office until the 2027 Annual Meeting of Stockholders” at VIR BIOTECHNOLOGY INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,290,7110 00For
BlackRock00 11,421,0080Abstain
State Street117,7100 5,061,1260Abstain
Fidelity1,830,9430 70,3970For
Charles Schwab00 769,4300Abstain
BRIDGEWAY FUNDS INC769,0000 00For
EA Series Trust458,0440 00For
Dimensional435,7040 00For
Invesco325,2040 00For
JPMorgan317,4650 00For
Columbia Threadneedle272,4560 00For
Capital Group258,4000 00For
Equitable00 228,7700Abstain
Jackson National209,7840 00For
TIAA205,3580 00For
Global X00 197,6300Abstain
Direxion Shares ETF Trust183,7730 00For
QUANTITATIVE MASTER SERIES LLC00 148,2300Abstain
American Century147,1120 00For
BNY Mellon126,5250 00For
Royce102,9000 00For
Principal98,1060 00For
ProShares97,5180 00For
ALPS ETF Trust95,2420 00For
Lincoln Financial5,5660 70,3000Abstain

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

4. To elect the following four nominees for director to hold office until the 2027 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Ramy Farid, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 106,416,937WITHHELD: 303,490

VIR BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Ramy Farid, Ph.D.”): 106,416,937 for, 303,490 withheld, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 135,843,560 outstanding shares: 78% for, 0.3% withheld (79% of the company cast a for/withheld vote).

The 73 asset managers below cast 100% of the shares they voted on this item FOR (37,335,155 for, 0 against).

FOR 99.9%
FOR: 37,335,155 (100.0%)ABSTAIN: 9,590 (0.0%)
Largest asset managers voting on “To elect the following four nominees for director to hold office until the 2027 Annual Meeting of Stockholders” at VIR BIOTECHNOLOGY INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,290,7110 00For
BlackRock11,421,0080 00For
State Street5,178,8360 00For
Fidelity1,901,3400 00For
Charles Schwab769,4300 00For
BRIDGEWAY FUNDS INC769,0000 00For
EA Series Trust458,0440 00For
Dimensional435,7040 00For
Invesco325,2040 00For
JPMorgan317,4650 00For
Columbia Threadneedle272,4560 00For
Capital Group258,4000 00For
Equitable228,7700 00For
Jackson National209,7840 00For
TIAA205,3580 00For
Global X197,6300 00For
Direxion Shares ETF Trust183,7730 00For
QUANTITATIVE MASTER SERIES LLC148,2300 00For
American Century147,1120 00For
BNY Mellon126,5250 00For
Royce102,9000 00For
Principal98,1060 00For
ProShares97,5180 00For
ALPS ETF Trust95,2420 00For
Lincoln Financial75,8660 00For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

5. To elect the following four nominees for director to hold office until the 2027 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Robert Nelsen

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

64% Majority: yes · of votes cast

FOR 64%WITHHELD 36%
FOR: 67,895,334WITHHELD: 38,825,093

VIR BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Robert Nelsen”): 67,895,334 for, 38,825,093 withheld, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 135,843,560 outstanding shares: 49.9% for, 29% withheld (79% of the company cast a for/withheld vote).

The 73 asset managers below cast 100% of the shares they voted on this item FOR (12,382,165 for, 0 against).

FOR 33%ABSTAIN 67%
FOR: 12,382,165 (33.2%)ABSTAIN: 24,962,580 (66.8%)
Largest asset managers voting on “To elect the following four nominees for director to hold office until the 2027 Annual Meeting of Stockholders” at VIR BIOTECHNOLOGY INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,221,3110 69,4000For
BlackRock00 11,421,0080Abstain
State Street52,4970 5,126,3390Abstain
Fidelity00 1,901,3400Abstain
Charles Schwab00 769,4300Abstain
BRIDGEWAY FUNDS INC00 769,0000Abstain
EA Series Trust00 458,0440Abstain
Dimensional00 435,7040Abstain
Invesco00 325,2040Abstain
JPMorgan00 317,4650Abstain
Columbia Threadneedle00 272,4560Abstain
Capital Group00 258,4000Abstain
Equitable00 228,7700Abstain
Jackson National00 209,7840Abstain
TIAA00 205,3580Abstain
Global X00 197,6300Abstain
Direxion Shares ETF Trust00 183,7730Abstain
QUANTITATIVE MASTER SERIES LLC00 148,2300Abstain
American Century00 147,1120Abstain
BNY Mellon00 126,5250Abstain
Royce102,9000 00For
Principal00 98,1060Abstain
ProShares00 97,5180Abstain
ALPS ETF Trust00 95,2420Abstain
Lincoln Financial00 75,8660Abstain

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

6. To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 118,125,237AGAINST: 679,046

VIR BIOTECHNOLOGY INC.’s own tally for this item (“Proposal 3. Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP”): 118,125,237 for, 679,046 against, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 135,843,560 outstanding shares: 87% for, 0.5% against (87% of the company cast a for/against vote).

The 73 asset managers below cast 99% of the shares they voted on this item FOR (36,877,111 for, 458,044 against).

FOR 99%
FOR: 36,877,111 (98.7%)AGAINST: 458,044 (1.2%)ABSTAIN: 9,590 (0.0%)
Largest asset managers voting on “To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company” at VIR BIOTECHNOLOGY INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard12,290,7110 00For
BlackRock11,421,0080 00For
State Street5,178,8360 00For
Fidelity1,901,3400 00For
Charles Schwab769,4300 00For
BRIDGEWAY FUNDS INC769,0000 00For
EA Series Trust0458,044 00Against
Dimensional435,7040 00For
Invesco325,2040 00For
JPMorgan317,4650 00For
Columbia Threadneedle272,4560 00For
Capital Group258,4000 00For
Equitable228,7700 00For
Jackson National209,7840 00For
TIAA205,3580 00For
Global X197,6300 00For
Direxion Shares ETF Trust183,7730 00For
QUANTITATIVE MASTER SERIES LLC148,2300 00For
American Century147,1120 00For
BNY Mellon126,5250 00For
Royce102,9000 00For
Principal98,1060 00For
ProShares97,5180 00For
ALPS ETF Trust95,2420 00For
Lincoln Financial75,8660 00For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Largest VIR BIOTECHNOLOGY INC. shareholders voting in 2023-2024

Ranked by the number of VIR BIOTECHNOLOGY INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 135,843,560 shares outstanding at the time of that meeting.

Top VIR BIOTECHNOLOGY INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1SB INVESTMENT ADVISERS (UK) LTD 12.28%
2BlackRock 11.25%
3ARCH Venture Management, LLC 9.51%
4Vanguard 9.16%
5State Street 8.87%
6BAILLIE GIFFORD & CO LTD 2.81%
7Citadel 1.61%
8GEODE CAPITAL MANAGEMENT, LLC 1.41%
9Fidelity 1.40%
10Charles Schwab 1.18%

Reported VIR BIOTECHNOLOGY INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

VIR BIOTECHNOLOGY INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
SVF Endurance (Cayman) Ltd. 12.28% DEF14A
BlackRock 11.75% 13F
Robert Nelsen 10.00% DEF14A
Entities affiliated with ARCH Venture Partners, L.P. 9.51% DEF14A
Vanguard Group 9.42% 13F
Glaxo Group Limited 6.29% DEF14A
State Street 5.20% 13F
George Scangos, Ph.D. 3.39% DEF14A
FMR (Fidelity) 2.68% 13F
Citadel Advisors 2.55% 13F

Percentages above are of 135,843,560 shares outstanding, as reported by VIR BIOTECHNOLOGY INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VIR BIOTECHNOLOGY INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At VIR BIOTECHNOLOGY INC.'s shareholder meeting held 2024-05-29, in the 2023-2024 proxy season, 229 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,653 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 79% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VIR BIOTECHNOLOGY INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-05-29.

VIR BIOTECHNOLOGY INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.